Trials / Completed
CompletedNCT01400425
Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 239 (actual)
- Sponsor
- Avid Radiopharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to evaluate whether a florbetapir F 18 PET scan can impact clinical thinking when physicians are determining the likely cause of a subject's cognitive impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | florbetapir F 18 | IV injection, 370 megabecquerel (MBq) (10 millicurie \[mCi\]), single dose |
Timeline
- Start date
- 2011-07-01
- Primary completion
- 2012-07-01
- Completion
- 2012-07-01
- First posted
- 2011-07-22
- Last updated
- 2013-03-29
- Results posted
- 2013-03-22
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01400425. Inclusion in this directory is not an endorsement.